Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference
- PMID: 16844457
- DOI: 10.1016/j.urology.2006.01.077
Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference
Abstract
Objectives: To evaluate the potential association between sexual motivation and patterns of erectile dysfunction (ED) therapy among a large cohort of localized prostate cancer treatment survivors.
Methods: The use of medications and devices to improve erections and sexual health-related quality of life (HRQOL) were evaluated using a mailed Expanded Prostate Cancer Index Composite survey administered to 896 men 4 to 8 years after brachytherapy, three-dimensional conformal external beam radiotherapy (3D-CRT), or radical prostatectomy and 112 control men. The responding participants (73% of those surveyed) were classified by prostate cancer treatment, sexual motivation, and ED therapy use. Bivariate and multivariate analyses were used to identify the factors associated with ED therapy use and sexual HRQOL outcome.
Results: The quality of erections unassisted by medications or devices was not different among the treatment groups. Prostate cancer survivors used medications or devices for ED more commonly than did the control men (30% versus 13%; P <0.01). One half of the prostate cancer survivors with ED reported indifference regarding their ED (small to no sexual bother despite absent or poor unassisted erections). Conversely, among men who were bothered by poor erections, 48% of the brachytherapy, 61% of the 3D-CRT, and 23% of radical prostatectomy subjects had never tried commonly available medications or devices to improve their erections (P <0.01). The current use of at least one erection aid was an independent determinant of more favorable sexual HRQOL (P <0.01).
Conclusions: Many men who are bothered by posttreatment ED reported never having tried medications or devices to improve their erections. The lack of ED therapy was more prevalent among patients with erectile concerns after brachytherapy or 3D-CRT than after radical prostatectomy, suggesting possible opportunities for improving sexual HRQOL among long-term survivors.
Similar articles
-
Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy.J Clin Oncol. 2005 Apr 20;23(12):2772-80. doi: 10.1200/JCO.2005.07.116. J Clin Oncol. 2005. PMID: 15837992
-
Defining sexual outcomes after treatment for localized prostate carcinoma.Cancer. 2002 Oct 15;95(8):1773-85. doi: 10.1002/cncr.10848. Cancer. 2002. PMID: 12365027
-
Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study.J Urol. 2005 Aug;174(2):646-50; discussion 650. doi: 10.1097/01.ju.0000165342.85300.14. J Urol. 2005. PMID: 16006930
-
Update on erectile dysfunction in prostate cancer patients.Curr Opin Urol. 2006 May;16(3):186-95. doi: 10.1097/01.mou.0000193407.05285.d8. Curr Opin Urol. 2006. PMID: 16679857 Review.
-
The psychosocial aspects of sexual recovery after prostate cancer treatment.Int J Impot Res. 2009 Mar-Apr;21(2):99-106. doi: 10.1038/ijir.2008.66. Epub 2009 Jan 22. Int J Impot Res. 2009. PMID: 19158798 Review.
Cited by
-
Prediction of erectile function following treatment for prostate cancer.JAMA. 2011 Sep 21;306(11):1205-14. doi: 10.1001/jama.2011.1333. JAMA. 2011. PMID: 21934053 Free PMC article.
-
Failure to address potential bias in non-randomised controlled clinical trials may cause lack of evidence on patient-reported outcomes: a method study.BMJ Open. 2014 Jun 4;4(6):e004720. doi: 10.1136/bmjopen-2013-004720. BMJ Open. 2014. PMID: 24898087 Free PMC article.
-
Men's sexual help-seeking and care needs after radical prostatectomy or other non-hormonal, active prostate cancer treatments.Support Care Cancer. 2021 May;29(5):2699-2711. doi: 10.1007/s00520-020-05775-5. Epub 2020 Sep 26. Support Care Cancer. 2021. PMID: 32978635
-
Initial report of the cancer Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function committee: review of sexual function measures and domains used in oncology.Cancer. 2009 Mar 15;115(6):1142-53. doi: 10.1002/cncr.24134. Cancer. 2009. PMID: 19195044 Free PMC article. Review.
-
Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.Radiat Oncol. 2013 Mar 13;8:58. doi: 10.1186/1748-717X-8-58. Radiat Oncol. 2013. PMID: 23497695 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials